Zebrafish reproductive-trigger hormone (kisspeptin-10, zebrafish)
A small hormone fragment from zebrafish that activates the brain's master switch for reproduction; used only as a lab research tool.
- Class
- Neuropeptide / reproductive axis regulator
- Status
- Not approved by FDA, EMA, MHRA, or Health Canada for any indication; investigational
- Best-supported effect
- Kisspeptin-54 as an IVF oocyte maturation trigger with reduced OHSS risk vs. hCG (multiple human RCTs); enhanced sexual and emotional brain processing in HSDD in both men and women (human RCTs)
- Main caveat
- No major-regulator approval for any use; strongest evidence is for kisspeptin-54 in specialist IVF trial settings; tachyphylaxis limits chronic dosing; research-chemical supply is not equivalent to GMP-grade trial material
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Zebrafish kisspeptin-10 (Kiss1-10) is the 10-amino-acid C-terminal fragment of the zebrafish (Danio rerio) Kiss1 prohormone — the fish ortholog of the mammalian kisspeptin that acts as the upstream master switch of the reproductive hormonal axis. The stored sequence YNLNSFGLRY corresponds to the "Y–Y" form of teleost Kiss1; the active peptide carries a C-terminal amide (YNLNSFGLRY-NH₂), which is essential for receptor binding and is not visible in the raw single-letter sequence (Akazome 2010, Journal of Fish Biology; Tsutsui 2010, Journal of Neuroendocrinology). Compared with human kisspeptin-10 (YNWNSFGLRY-NH₂), the zebrafish form differs at position 3 (Leu instead of Trp).
This card represents the zebrafish Kiss1 decapeptide as a comparative-endocrinology and neuroscience research tool, not a clinical compound. The broader kisspeptin family is investigated for human reproductive applications; the zebrafish form is used in fish neuroendocrinology, in studies of the kisspeptin system's evolutionary history, and in dissecting non-reproductive behavioral functions of kisspeptin signaling.
History
Kisspeptin was first identified in 1996 as a melanoma metastasis-suppressor gene product, and the name reflects a playful nod to Hershey, Pennsylvania (home of Hershey's Kisses). Its receptor (then orphan GPR54, now KISS1R / Kiss1r) was deorphanized in 2001 when Kotani and colleagues showed that kisspeptin peptides are the natural ligands (Kotani 2001, Journal of Biological Chemistry). The reproductive role emerged in 2003, when loss-of-function mutations in the receptor were linked to hypogonadotropic hypogonadism, establishing kisspeptin as the upstream regulator of GnRH pulse generation (Tsutsui 2010, Journal of Neuroendocrinology; Kirby 2010, Pharmacological Reviews).
The discovery that fish carry two kisspeptin genes — kiss1 and kiss2 — followed in 2008–2009 (Biran et al. 2008; van Aerle et al. 2008; Kitahashi et al. 2009, Endocrinology), a consequence of the teleost-specific whole-genome duplication early in ray-finned fish evolution (Akazome 2010, Journal of Fish Biology; Pasquier 2012, Frontiers in Endocrinology). The C-terminal decapeptides of the two paralogs differ both in sequence and in C-terminal residue: zebrafish Kiss1-10 is an RY-amide form (YNLNSFGLRY-NH₂), while zebrafish Kiss2-10 is an RF-amide form (FNYNPFGLRF-NH₂); only the central -N-N-FGLR- motif is shared (Akazome 2010, Journal of Fish Biology).
A surprise from the zebrafish work: while Kiss2 neurons sit in the hypothalamus and connect to the pituitary in a recognizable mammalian-style reproductive pattern, Kiss1 neurons in zebrafish are concentrated in the habenula — a structure that in mammals is associated with reward, aversion, and behavioral control rather than reproduction (Ogawa 2018, Frontiers in Endocrinology). That anatomical mismatch led to a body of work on zebrafish Kiss1 as a behavioral neuromodulator distinct from its strictly reproductive cousins.
What it does
In zebrafish biology the Kiss1-10 peptide has two largely separable roles, mapped onto two anatomically distinct neuron populations:
Reproductive axis (Kiss2-dominated, with Kiss1 contribution). Kisspeptins activate GnRH neurons that drive gonadotropin (LH, FSH) release and downstream gonadal steroidogenesis — the same fundamental axis as in mammals. In transgenic zebrafish using a GnRH3:emerald-GFP reporter, Kiss1 (but not Kiss2) stimulated proliferation of terminal-nerve and hypothalamic GnRH3 neurons during embryogenesis, and increased their spontaneous firing in adults via whole-cell patch-clamp recordings (Servili et al. 2014, PLOS One).
Habenular / behavioral pathway (Kiss1-specific). Kiss1 neurons in the ventral habenula project through the fasciculus retroflexus to the median raphe, where they modulate serotonergic output. Kiss1 administration upregulates serotonin-pathway genes (pet1, slc6a4a/sert) in the raphe (Ogawa, Nathan and Parhar 2014, PNAS; Ogawa 2018, Frontiers in Endocrinology). Behaviorally, exogenous Kiss1 suppresses the alarm-substance-evoked fear response, and selective ablation of Kiss-receptor-expressing habenular neurons via a Kiss1-saporin conjugate likewise reduces fear behavior — implicating habenular Kiss1 as an intrinsic anti-fear neuromodulator (Ogawa 2014, PNAS).
Beyond reproduction and fear, kisspeptin has been associated with broader limbic and behavioral integration in vertebrates more generally (Hellier 2019, Seminars in Reproductive Medicine; Mills 2019, Seminars in Reproductive Medicine).
Mechanism
Kisspeptins act through the kisspeptin receptor family, originally called GPR54 and named Kiss1R in mammals. Teleosts carry two receptor paralogs — most commonly designated Kissr2 and Kissr3 (older nomenclature: kiss1ra/kiss1rb) — arising from the same teleost-specific genome duplication that produced the two ligands (Pasquier 2012, Frontiers in Endocrinology; Mechaly 2018, Frontiers in Endocrinology). In zebrafish, the habenular Kiss1 system signals through the habenula-expressed receptor (Kissr2 in current nomenclature), while the other paralog is more broadly distributed (Ogawa 2018, Frontiers in Endocrinology).
The receptors are Gq/11-coupled GPCRs; in mammalian and amphibian systems, ligand binding activates phospholipase C and PKC signaling, and the same coupling has been demonstrated for fish Kissrs expressed in COS-7 cells using serum-response-element reporter assays (Akazome 2010, Journal of Fish Biology; Kirby 2010, Pharmacological Reviews). In the habenular circuit, Kiss1 neurons are glutamatergic and their axons form close contacts with glutamatergic and GABAergic interneurons in the median raphe before the signal reaches serotonergic neurons (Ogawa 2018, Frontiers in Endocrinology).
The C-terminal amide is mechanistically essential: removing it abolishes receptor binding across the kisspeptin family. The RY-amide vs RF-amide distinction between Kiss1 and Kiss2 contributes to differential receptor preference in sea bass and other teleosts (Pasquier 2012, Frontiers in Endocrinology).
Evidence
- Animal (zebrafish-specific): Multiple peer-reviewed studies establish the dual habenular/hypothalamic kisspeptin system, the Kiss1 projection from habenula to median raphe, the serotonergic gene-expression response to Kiss1 in the raphe, and the suppression of alarm-substance-evoked fear by Kiss1 (Ogawa 2014, PNAS; Ogawa 2018, Frontiers in Endocrinology; Servili 2014, PLOS One).
- Animal (other teleosts): Independent characterization of the two-paralog system across pejerrey, medaka, sea bass, and other fish (Mechaly 2018, Frontiers in Endocrinology; Akazome 2010, Journal of Fish Biology; Pasquier 2012, Frontiers in Endocrinology).
- In vitro: Functional characterization of fish Kissrs in heterologous expression systems (COS-7 cells) confirms Gq/11 coupling on ligand binding, consistent with mammalian KISS1R pharmacology (Akazome 2010, Journal of Fish Biology).
- Comparative / evolutionary: Vertebrate-wide reconstruction of kisspeptin and Kissr lineages places the zebrafish Kiss1/Kiss2 pair within a broader teleost duplication, with both parallel and divergent features versus tetrapod systems (Pasquier 2012, Frontiers in Endocrinology; Tsutsui 2010, Journal of Neuroendocrinology).
- Human: Not applicable to this zebrafish-derived sequence. Human clinical evidence concerns the human kisspeptin-10 / kisspeptin-54 forms (e.g. acute gonadotropin stimulation; the kisspeptin-54 IVF trigger work; Jayasena 2009, Journal of Clinical Endocrinology & Metabolism), which differ in sequence and clinical context from the zebrafish form.
Known effects
- GnRH neuron activation (zebrafish) — Embryonic proliferation and adult firing of GnRH3 neurons increased by Kiss1; Kiss2 lacks this effect in matched assays (Servili 2014, PLOS One). Evidence level: preclinical (teleost).
- Habenular–raphe serotonergic modulation — Upregulation of serotonin-related genes (pet1, sert) in the median raphe following Kiss1 administration (Ogawa 2014, PNAS; Ogawa 2018, Frontiers in Endocrinology). Evidence level: preclinical (teleost).
- Fear-response suppression — Exogenous Kiss1 blunts alarm-substance-evoked fear in zebrafish; targeted ablation of Kiss-receptor-expressing habenular neurons via a Kiss1-saporin conjugate produces the same reduction (Ogawa 2014, PNAS). Evidence level: preclinical (teleost).
- Comparative reproductive biology — Both Kiss1 and Kiss2 modulate downstream gonadotropin release in fish, with relative roles differing across species (Pasquier 2012, Frontiers in Endocrinology; Mechaly 2018, Frontiers in Endocrinology). Evidence level: preclinical (multiple teleosts).
- Receptor binding at fish Kissr — The zebrafish Kiss1 decapeptide activates fish Kissrs via Gq/11-coupled signaling (Akazome 2010, Journal of Fish Biology; Kirby 2010, Pharmacological Reviews). Evidence level: mechanistic / in vitro.
Regulatory status
The zebrafish Kiss1 decapeptide is a research peptide. It is not a drug candidate in human development and holds no marketing authorization from FDA, EMA, MHRA, Health Canada, or any other reference regulator. It is used as a tool peptide in fish neuroendocrinology and comparative-vertebrate research. WADA's peptide-hormone catch-all language applies to kisspeptin family members in athletic-competition contexts via their LH/FSH-stimulating activity; the zebrafish form is not specifically named on the WADA prohibited list.
Open questions
- Function of habenular Kiss1 in mammals. Habenular kisspeptin neurons are prominent in zebrafish; the equivalent population in mammals is sparse, and whether the fear / anti-aversion role generalizes to the mammalian habenula remains unresolved (Ogawa 2018, Frontiers in Endocrinology).
- Why two paralogs, two receptors? The functional rationale for retaining both Kiss1 and Kiss2 (with two cognate receptors) over hundreds of millions of years of teleost evolution is not fully explained — some species have lost one paralog, others rely on alternative splicing of receptor transcripts to fine-tune signaling (Mechaly 2018, Frontiers in Endocrinology).
- Cross-paralog receptor selectivity. The relative agonist potencies of Kiss1-10 and Kiss2-10 at zebrafish Kissr2 vs Kissr3 remain incompletely mapped, with results varying across species and assay systems (Pasquier 2012, Frontiers in Endocrinology).
- GnIH / kisspeptin integration. Gonadotropin-inhibitory hormone (GnIH) and kisspeptin together coordinate reproductive output; how the habenular Kiss1 pool integrates with GnIH-driven inhibition in fish is an active area (Tsutsui 2010, Journal of Neuroendocrinology).
- Translatability of fear-modulation findings. Whether the Kiss1 → median raphe → serotonergic pathway demonstrated in zebrafish has homologous correlates in other vertebrates, and whether it could illuminate kisspeptin's contributions to mood and emotional processing observed in human brain-imaging studies, remains open (Mills 2019, Seminars in Reproductive Medicine; Hellier 2019, Seminars in Reproductive Medicine).
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could a targeted peptide rebuild the missing nerve cells that cause delayed or absent puberty, rather than just artificially flooding the body with hormones?
Some people are born with too few of the neurons that start puberty, leading to infertility and developmental problems (Kallmann syndrome and similar conditions). If this holds, a Kiss1-based drug could replenish those neurons in the brain without accidentally triggering premature puberty, offering a gentler, structural repair rather than a hormone jolt.
Does this peptide ease fear and anxiety by lifting a suppressor off the brain's serotonin system rather than stimulating serotonin directly?
Understanding exactly how a calming signal travels through the brain matters for designing better anxiety or PTSD treatments. If this circuit works through a GABA intermediate, drugs targeting it could work alongside SSRIs rather than duplicating them, potentially helping people who do not respond to existing antidepressants.
Could a one-letter change in the peptide's building blocks make it activate fish reproductive receptors without interfering with the human version?
Fish farming relies on controlling reproduction in large numbers of fish. If this selectivity holds, a zebrafish-derived kisspeptin analog could be used in aquaculture to manage breeding cycles without posing hormonal risks to people or other animals that are accidentally exposed to it.
If a molecule grips a receptor at two separate spots, could chemists shorten it from the less important end to make a more stable drug without losing effect?
Peptide drugs are often fragile and expensive to manufacture. If the two critical binding anchors are confirmed, chemists could trim away the less important tip of the molecule first, creating a shorter, more stable version that is cheaper to produce and survives longer in the body, potentially useful for any condition this peptide treats.
Could activating a deeply conserved anti-aversion pathway in the brain offer a new way to treat depression that has not responded to existing drugs?
Treatment-resistant depression affects millions of people who do not improve on standard antidepressants. If the habenula-based kisspeptin circuit functions as an evolutionarily preserved brake on negative feelings, targeting it could open a non-hormonal, non-monoamine route to relief, potentially complementing ketamine or other rapid-acting approaches for the hardest cases to treat.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.9568769931793213 | boltz-2 |
| ranking score | 0.7699713706970215 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | colabfold_local |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-22 |
▸citationbibtex
@peptide{pep10709,
sequence = {YNLNSFGLRY},
target = {kiss1r},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}